MiniMed Group, Inc. (MMEDV) SEC Filings & Earnings Calls

Transition risks as a newly independent company; no financial guidance provided.

“Forward-looking statements caution about risks and uncertainties; no specific financial metrics disclosed.”

CGM Pricing Pressure

“We have observed pricing pressure on CGMs globally, particularly in certain international markets.” · word for word

CGM Mix Margin Pressure

“The decrease in gross margin was primarily driven by the higher mix of Simplera sensors, which currently have a lower gross margin than the Company's legacy and Instinct sensors.” · word for word

Medtronic Dependency

“As of July 31, 2026, Medtronic continued to own approximately 90% of our outstanding common stock.” · word for word

Extra week benefit (~4-6%) in Q1 may inflate reported growth; organic growth excluding extra week was low-double digit.

“included an approximate 4-6% benefit from extra week as a result of 52-53 week fiscal calendar; excluding extra week benefit, the Company generated low-double digit organic growth”

Controlled company governance risk

“MiniMed has availed itself of the “controlled company” exemption under the corporate governance rules of Nasdaq.” · word for word

Medtronic divestment uncertainty

“Medtronic has no obligation to pursue or consummate any further dispositions of its equity interest in MiniMed, including through the Divestment, by any specified date or at all.” · word for word

IPO Grant PSUs may not vest

“If such stock price is not achieved on the Divestment Date and prior to the vesting date, then no performance-based restricted stock units will vest.” · word for word

Key executive departure

“On July 30, 2026, Ms. Nelson Wills notified the Company of her decision to resign from her position, effective September 25, 2026.” · word for word

Tax indemnification liability

“MiniMed’s indemnification obligations to Medtronic under the Tax Matters Agreement are not limited in any amount or subject to any cap.” · word for word

Loss of key legal and governance leadership; successor search underway; potential temporary gap in compliance oversight.

“MiniMed is conducting a search for a successor, appreciates Ms. Nelson Wills’s helpful assistance in facilitating a seamless leadership transition of her duties, and remains committed to maintaining strong legal, governance, and compliance oversight throughout this transition.” · word for word

Profitability deterioration

“Net loss represented 10% of our revenue and our Adjusted EBITDA represented 6% of our revenue during fiscal year 2026.” · word for word

GLP-1 competitive threat

“We expect that GLP-1s may reduce the number of people with T2D who require intensification of their therapy.” · word for word

U.S. revenue growth slow at 1.5% due to product transition; new launches may not fully offset.

“U.S. net sales of $238 million grew 1.5% as reported and organic, as early FDA clearance of MiniMed TM Flex shifted demand” · word for word

Asset write-offs from manufacturing agreement termination

“The increase in cost of products sold as a percentage of net sales for the three months ended January 23, 2026 as primarily driven by 1,130 basis points (“bps”) increase from the asset write offs” · word for word

Low cash position post-IPO

“As of January 23, 2026, we had $10 million in cash and cash equivalents.” · word for word

Dependence on Medtronic for transition services

“Medtronic will continue to provide certain services to us on a transitional basis” · word for word